600252 Stock Overview
Researches, develops, manufactures, and sells pharmaceuticals in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Guangxi Wuzhou Zhongheng Group Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.46 |
| 52 Week High | CN¥3.28 |
| 52 Week Low | CN¥1.87 |
| Beta | 0.28 |
| 1 Month Change | -7.17% |
| 3 Month Change | 2.93% |
| 1 Year Change | -2.77% |
| 3 Year Change | -40.15% |
| 5 Year Change | -25.00% |
| Change since IPO | 328.46% |
Recent News & Updates
Health Check: How Prudently Does Guangxi Wuzhou Zhongheng GroupLtd (SHSE:600252) Use Debt?
Dec 11
There's Reason For Concern Over Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Massive 26% Price Jump
Nov 05Recent updates
Health Check: How Prudently Does Guangxi Wuzhou Zhongheng GroupLtd (SHSE:600252) Use Debt?
Dec 11There's Reason For Concern Over Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Massive 26% Price Jump
Nov 05Investors Don't See Light At End Of Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Tunnel
Jun 19Guangxi Wuzhou Zhongheng GroupLtd (SHSE:600252) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Apr 05Guangxi Wuzhou Zhongheng GroupLtd (SHSE:600252) Has Debt But No Earnings; Should You Worry?
Mar 15Shareholder Returns
| 600252 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.0% | -0.08% | 1.0% |
| 1Y | -2.8% | -6.0% | 8.2% |
Return vs Industry: 600252 exceeded the CN Pharmaceuticals industry which returned -6% over the past year.
Return vs Market: 600252 underperformed the CN Market which returned 8.2% over the past year.
Price Volatility
| 600252 volatility | |
|---|---|
| 600252 Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CN Market | 12.2% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 600252 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600252's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 2,886 | Yidong Ni | www.wz-zhongheng.com |
Guangxi Wuzhou Zhongheng Group Co.,Ltd, together with its subsidiaries, researches, develops, manufactures, and sells pharmaceuticals in China. The company offers traditional Chinese medicines; and xueshuantong for shooting, zhonghua dieda pills, angong niuhuang pills, shedan chuanbei liquid, fuyanjing capsules, jieshitong tablets, yanjianning tablets, sodium fluorescein injection under the Zhonghua, Chenzhong, and Zhongheng brands for cardiovascular and cerebrovascular, neurology, endocrinology, orthopedics,ophthalmology, gynecology, ediatrics, respiratory, urinary system, and other fields. It also provides clindamycin hydrochloride injection, naloxone hydrochloride injection, yanhuning injection, tranexamic acid injection, tranexamic acid sodium chloride injection, fludarabine phosphate for injection, esomeprazole sodium for injection, hydrochloric acid, levofloxacin sodium chloride injection, alanyl-glutamine injection for anti-tumor drugs, digestive system drugs parenteral nutrition, and anti-infection.
Guangxi Wuzhou Zhongheng Group Co.,Ltd Fundamentals Summary
| 600252 fundamental statistics | |
|---|---|
| Market cap | CN¥8.38b |
| Earnings (TTM) | -CN¥24.94m |
| Revenue (TTM) | CN¥2.86b |
2.9x
P/S Ratio-326.9x
P/E RatioIs 600252 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600252 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.86b |
| Cost of Revenue | CN¥1.62b |
| Gross Profit | CN¥1.24b |
| Other Expenses | CN¥1.26b |
| Earnings | -CN¥24.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 29, 2025
| Earnings per share (EPS) | -0.0075 |
| Gross Margin | 43.24% |
| Net Profit Margin | -0.87% |
| Debt/Equity Ratio | 21.3% |
How did 600252 perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield-137%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 10:17 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guangxi Wuzhou Zhongheng Group Co.,Ltd is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chao Li | Citic Securities Co., Ltd. |
| Weina Jiang | Everbright Securities Co. Ltd. |
| Bin Wu | Founder Securities Co., Ltd. |